UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction | (Commission | (IRS Employer |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
| Trading Symbol(s) |
| Name of Each Exchange on Which Registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07.Submission of Matters to a Vote of Security Holders.
On July 25, 2023, Kiromic BioPharma, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Meeting”).
As of June 9, 2023, the record date for the Meeting, there were 1,176,260 shares of our common stock outstanding.
At the Meeting, the stockholders voted and approved the following three proposals and cast their votes as follows:
1. To elect the three (3) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified including Pietro Bersani, Americo Cicchetti and Michael Nagel.
Name |
| Votes For |
| Withhold |
| Broker Non-Vote |
Pietro Bersani | 201,006 | 111,697 | 193,715 | |||
Americo Cicchetti | 195,074 | 117,629 | 193,715 | |||
Michael Nagel | 154,911 | 157,792 | 193,715 |
2. To ratify the appointment of Whitley Penn, LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023.
Votes For |
| Votes Against |
| Votes Abstained |
| Broker Non-Vote |
394,137 | 15,347 | 96,934 | 0 |
3. To approve the amendment to the Company’s 2021 Omnibus Equity Incentive Plan.
Votes For |
| Votes Against |
| Votes Abstained |
| Broker Non-Vote |
166,575 | 121,013 | 25,115 | 193,715 |
2